Study design (if review, criteria of inclusion for studies)
Cross-over design. RCT.
Participants
8 males; 6 females; median age 25 years, range 18 - 37 years. 18 participants with CF recruited only 14 completed the study. CF diagnosed on basis of clinical criteria (not stated) and sweat test.
Interventions
Control group: nebulised saline, 3.5 ml 4x daily for 25 weeks. Treatment group: nebulised amiloride hydrochloride 5 mmol/L, 3.5 ml 4x daily for 25 weeks followed by a 2 - 4 week washout period.
Outcome measures
Decline in FVC and FEV1 (all respiratory treatment stopped at beginning of study period); sputum rheology; need for extra treatment; acquisition of respiratory pathogens.